Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity.
Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity.
复制标题
通过具有固有 PDAC 选择性的荧光团评估人类胰腺癌组织和癌前病变。
DOI：
10.1016/j.ymeth.2019.06.008
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Strongin,RobertM
中科院分区：
文献类型：
--
作者：
Munhenzva,IanR;Barth,ConnorW;Sibrian-Vazquez,Martha;Wang,LeiG;Escobedo,JorgeO;Gibbs,SummerL;Strongin,RobertM
目前胰腺导管腺癌(PDAC)的五年存活率为5%，而且诊断较晚，缺乏针对PDAC的术中指导以确保完全切除，以及现有治疗方法的无效。以前，利用化合物1，一种具有固有的PDAC选择性的荧光团，PDAC在小鼠活体模型中被可视化。在目前的研究中，以人的PDAC组织为靶点。Compon1选择性地对腺癌的导管和周围间质进行染色，使PDAC能够在高对比度的冰冻组织切片上成像。为了增强1在术中应用的潜力，对EX活体染色方案进行了优化，以快速评估边缘，最终染色时间为 ~15 分钟。为了衡量诊断性能，测量了受试者工作特征(ROC)曲线下的面积，以识别导管腺癌和间质。明亮的荧光对比度使得能够在人体组织阵列样本中定量测定PDAC(或癌前病变)与健康胰腺组织。
The current five-year survival rate of <5% for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound1,a fluorophore with inherent PDAC selectivity, PDAC was visualized bothin vivoandex vivoin a murine model. In the current study, human PDAC tissue is targeted. Compound1selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of1for intraoperative applications, theex vivostaining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.